Further study is thus warranted on the rates of BRAF mutation in various grades of NET as well as NEC, and if variances in these findings are clinically relevant to predicting disease behavior beyond known factors such as Ki-67. This evidence concerns the gene BRAF and neuroendocrine carcinoma.